# Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

> **NCT00521859** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Cloretazine
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT00521859
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2012-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521859, "Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00521859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*